IDO expression has a controversial impact in the TME with higher IDO expression correlated with a decrease in tumor growth and longer survival in patients with prostate cancer [335], hepatocellular carcinoma [336] and renal cell carcinoma [337]. This evidence concerns the gene IDO1 and renal cell carcinoma.